These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 22262593)

  • 41. Near real-time vaccine safety surveillance with partially accrued data.
    Greene SK; Kulldorff M; Yin R; Yih WK; Lieu TA; Weintraub ES; Lee GM
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):583-90. PubMed ID: 21538670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exposure-time-varying hazard function ratios in case-control studies of drug effects.
    Guess HA
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):81-92. PubMed ID: 16287211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methodological problems of time-related variables in occupational cohort studies.
    Pearce N
    Rev Epidemiol Sante Publique; 1992; 40 Suppl 1():S43-54. PubMed ID: 1626105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The case-crossover and case-time-control designs in pharmacoepidemiology.
    Donnan PT; Wang J
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):259-62. PubMed ID: 11501340
    [No Abstract]   [Full Text] [Related]  

  • 46. Guidelines for good database selection and use in pharmacoepidemiology research.
    Hall GC; Sauer B; Bourke A; Brown JS; Reynolds MW; LoCasale R
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):1-10. PubMed ID: 22069180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.
    Cadarette SM; Maclure M; Delaney JAC; Whitaker HJ; Hayes KN; Wang SV; Tadrous M; Gagne JJ; Consiglio GP; Hallas J
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):671-684. PubMed ID: 33715267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Interpretation of epidemiologic studies. Type of study, elements of bias, causality].
    Touzet S; Colin C
    Rev Prat; 1999 Oct; 49(16):1797-804. PubMed ID: 10578612
    [No Abstract]   [Full Text] [Related]  

  • 49. Research challenges: overview of epidemiological study designs.
    Bombardier C
    J Rheumatol Suppl; 1988 Oct; 17():5-8. PubMed ID: 3204620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study.
    Uddin MJ; Groenwold RH; de Boer A; Belitser SV; Roes KC; Hoes AW; Klungel OH
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):165-77. PubMed ID: 24306965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bias in research.
    Agabegi SS; Stern PJ
    Am J Orthop (Belle Mead NJ); 2008 May; 37(5):242-8. PubMed ID: 18587501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reporting participation in epidemiologic studies: a survey of practice.
    Morton LM; Cahill J; Hartge P
    Am J Epidemiol; 2006 Feb; 163(3):197-203. PubMed ID: 16339049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case-only designs for studying the association of antidepressants and hip or femur fracture.
    de Groot MC; Candore G; Uddin MJ; Souverein PC; Ali MS; Belitser SV; Huerta C; Groenwold RH; Alvarez Y; Slattery J; Korevaar J; Hoes AW; Roes KC; de Boer A; Douglas IJ; Schlienger RG; Reynolds R; Klungel OH; Gardarsdottir H
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25 Suppl 1():103-13. PubMed ID: 27038356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
    Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Control for seasonal variation and time trend in case-crossover studies of acute effects of environmental exposures.
    Bateson TF; Schwartz J
    Epidemiology; 1999 Sep; 10(5):539-44. PubMed ID: 10468428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Should we use a case-crossover design?
    Maclure M; Mittleman MA
    Annu Rev Public Health; 2000; 21():193-221. PubMed ID: 10884952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of health care databases in pharmacoepidemiology.
    Hennessy S
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):311-3. PubMed ID: 16611207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research on drug safety and effectiveness using pharmacoepidemiological databases.
    Andersen M
    J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
    [No Abstract]   [Full Text] [Related]  

  • 60. Data safety and drug safety in Germany: a closing gap?
    Rathmann W
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):625-30. PubMed ID: 11980251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.